95 related articles for article (PubMed ID: 14583491)
1. Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Ramji S; Lee C; Inaba T; Patterson AV; Riddick DS
Cancer Res; 2003 Oct; 63(20):6914-9. PubMed ID: 14583491
[TBL] [Abstract][Full Text] [Related]
2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
3. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects.
Bartoszek A
Acta Biochim Pol; 2002; 49(2):323-31. PubMed ID: 12362973
[TBL] [Abstract][Full Text] [Related]
4. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells.
Baumann RP; Hodnick WF; Seow HA; Belcourt MF; Rockwell S; Sherman DH; Sartorelli AC
Cancer Res; 2001 Nov; 61(21):7770-6. PubMed ID: 11691791
[TBL] [Abstract][Full Text] [Related]
5. Activation of mitomycin C by NADPH:cytochrome P-450 reductase.
Bligh HF; Bartoszek A; Robson CN; Hickson ID; Kasper CB; Beggs JD; Wolf CR
Cancer Res; 1990 Dec; 50(24):7789-92. PubMed ID: 2123741
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
7. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
8. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes.
Kim C; Crane FL; Faulk WP; Morré DJ
J Biol Chem; 2002 May; 277(19):16441-7. PubMed ID: 11875069
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Lu H; Waxman DJ
Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
[TBL] [Abstract][Full Text] [Related]
12. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
13. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.
Li X; Lu Y; Liang K; Liu B; Fan Z
Breast Cancer Res; 2005; 7(5):R589-97. PubMed ID: 16168102
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F; González-Navarrete I; Bragado R; Dalmases A; Menéndez S; Cortes-Sempere M; Suárez C; Oliva C; Servitja S; Rodriguez-Fanjul V; Sánchez-Pérez I; Campas C; Corominas JM; Tusquets I; Bellosillo B; Serrano S; Perona R; Rovira A; Albanell J
Clin Cancer Res; 2009 May; 15(10):3530-9. PubMed ID: 19417026
[TBL] [Abstract][Full Text] [Related]
15. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Paine MJ; Korytowska A; Serwatka K; Piotrowska S; Wolf CR; Tarasiuk J
Cancer Lett; 2007 Jan; 245(1-2):252-62. PubMed ID: 16574318
[TBL] [Abstract][Full Text] [Related]
16. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Hoke EM; Maylock CA; Shacter E
Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
[TBL] [Abstract][Full Text] [Related]
17. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
18. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization of NADPH:cytochrome c (P450) reductase enhances the cytotoxicity of mitomycin C to Chinese hamster ovary cells.
Seow HA; Belcourt MF; Penketh PG; Hodnick WF; Tomasz M; Rockwell S; Sartorelli AC
Mol Pharmacol; 2005 Feb; 67(2):417-23. PubMed ID: 15547247
[TBL] [Abstract][Full Text] [Related]
20. Production of superoxide radical in reductive metabolism of a synthetic food-coloring agent, indigocarmine, and related compounds.
Kohno Y; Kitamura S; Yamada T; Sugihara K; Ohta S
Life Sci; 2005 Jun; 77(6):601-14. PubMed ID: 15921992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
